Summary:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Safety, Tolerability, Immunogenicity and Efficacy of a Variant-Adapted BNT162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age
Criteria:
- Be 50 through 64 years of
age
- Be Healthy participants
who are determined healthy by medical history, physical examination
- Not have a diagnosis of Cancer, cerebrovascular disease, chronic kidney, lung, liver disease, or cystic fibrosis; diabetes (type 1 or 2); disabilities, cardiovascular disease, hemoglobin disorders, HIV, mental health or neurological disorders; obesity (BMI ≥30); pregnancy or breastfeeding; immunocompromised state; physical inactivity; current or former smoking; organ or stem cell transplant; substance use disorder; or tuberculosis.
Qualified Participants May Receive:
$150 per completed visit in Clinic